TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1

Oral blood coagulation inhibitors and their receptors, such as factor Xa (FXa), thrombin, and the thrombin receptor protease-activated receptor 1 (PAR1), are entered into clinical trials for acute coronary syndrome therapy; however, the results obtained so far are different for each drug. The underl...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinozawa, Emiko, Nakayama, Masaharu, Imura, Yoshimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290330/
https://www.ncbi.nlm.nih.gov/pubmed/30568593
http://dx.doi.org/10.3389/fphar.2018.01431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290330/
https://www.ncbi.nlm.nih.gov/pubmed/30568593
http://dx.doi.org/10.3389/fphar.2018.01431

Ejemplares similares